Plant-made vaccines and reagents for the One Health initiative

References

• Jeggo M, Mackenzie JS. Defining the future of one health. Microbiol Spectrum. 2014;2:OH–0007. doi:10.1128/microbiolspec.OH-0007-2012. PMID:26082113
   PubMedGoogle Scholar
• Monath TP. Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine. 2013;31:5321–38. doi:10.1016/j.vaccine.2013.09.029. PMID:24060567
   PubMed Web of Science ®Google Scholar
• Bengis RG, Frean J. Anthrax as an example of the one health concept. Rev Sci Tech. 2014;33:593–604. PMID:25707186
   PubMed Web of Science ®Google Scholar
• Cleaveland S, Lankester F, Townsend S, Lembo T, Hampson K. Rabies control and elimination: a test case for one health. Vet Rec. 2014;175:188–93. doi:10.1136/vr.g4996. PMID:25172649
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Angulo C, Meza B. Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends Biotechnol. 2016;34:124–36. doi:10.1016/j.tibtech.2015.11.007. PMID:26708345
   PubMed Web of Science ®Google Scholar
• Topp E, Irwin R, McAllister T, Lessard M, Joensuu JJ, Kolotilin I, Conrad U, Stoger E, Mor T, Warzecha H, et al. The case for plant-made veterinary immunotherapeutics. Biotechnol Adv. 2016;34:597–604. doi:10.1016/j.biotechadv.2016.02.007. PMID:26875776
   PubMed Web of Science ®Google Scholar
• Merlin M, Pezzotti M, Avesani L. Edible plants for oral delivery of biopharmaceuticals. Br J Clin Pharmacol. 2017;83:71–81. doi:10.1111/bcp.12949. PMID:27037892
   PubMed Web of Science ®Google Scholar
• Steele JF, Peyret H, Saunders K, Castells-Graells R, Marsian J, Meshcheriakova Y, Lomonossoff GP. Synthetic plant virology for nanobiotechnology and nanomedicine. WIREs Nanomed Nanobiotechnol. 2017;9:e1447. doi:10.1002/wnan.1447. PMID:28078770
   PubMedGoogle Scholar
• Rybicki EP. Plant-based vaccines against viruses. Virol J. 2014;11:205. doi:10.1186/s12985-014-0205-0. PMID:25465382
   PubMed Web of Science ®Google Scholar
• D'Aoust MA, Lavoie PO, Couture MM, Trepanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vezina LP. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008;6:930–40. doi:10.1111/j.1467-7652.2008.00384.x
   PubMed Web of Science ®Google Scholar
• Kahn RE, Ma W, Richt JA. Swine and influenza: a challenge to one health research. Curr Top Microbiol Immunol. 2014;385:205–18. doi:10.1007/82_2014_392
   PubMed Web of Science ®Google Scholar
• Leclerc D, Rivest M, Babin C, Lopez-Macias C, Savard P. A novel M2e based flu vaccine formulation for dogs. PLoS One. 2013;8:e77084. doi:10.1371/journal.pone.0077084. PMID:24098576
   PubMed Web of Science ®Google Scholar
• Mortimer E, Maclean JM, Mbewana S, Buys A, Williamson AL, Hitzeroth, II, Rybicki EP. Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol. 2012;12:14. doi:10.1186/1472-6750-12-14. PMID:22536810
   PubMed Web of Science ®Google Scholar
• Mbewana S, Mortimer E, Pera FF, Hitzeroth, II, Rybicki EP. Production of H5N1 Influenza Virus Matrix Protein 2 Ectodomain Protein Bodies in Tobacco Plants and in Insect Cells as a Candidate Universal Influenza Vaccine. Front Bioeng Biotechnol. 2015;3:197. doi:10.3389/fbioe.2015.00197. PMID:26697423
   PubMedGoogle Scholar
• Mackenzie JS, Field HE, Guyatt KJ. Managing emerging diseases borne by fruit bats (flying foxes), with particular reference to henipaviruses and Australian bat lyssavirus. J Applied Microbiol. 2003;94:59S–69S
   PubMed Web of Science ®Google Scholar
• Ashraf S, Singh PK, Yadav DK, Shahnawaz M, Mishra S, Sawant SV, Tuli R. High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol. 2005;119:1–14. doi:10.1016/j.jbiotec.2005.06.009. PMID:16038998
   PubMed Web of Science ®Google Scholar
• Loza-Rubio E, Rojas-Anaya E, Lopez J, Olivera-Flores MT, Gomez-Lim M, Tapia-Perez G. Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein. Vaccine. 2012;30:5551–6. doi:10.1016/j.vaccine.2012.06.039. PMID:22749836
   PubMed Web of Science ®Google Scholar
• D'Aoust M-A, Lavoie P-O, Vezina L-P, Couture M in https://www.google.com/patents/EP2718428A4?cl=en, Vol. EP2718428 A4. (ed. Organisation EP) (Europe; 2012)
   Google Scholar
• Medicago. Medicago Announces Expansion of Pipeline with the Development of a Vaccine for Rabies. 2012 [ accessed April 12th 2017]. http://www.prnewswire.com/news-releases/medicago-announces-expansion-of-pipeline-with-the-development-of-a-vaccine-for-rabies-137659043.html
   Google Scholar
• van Dolleweerd CJ, Teh AY, Banyard AC, Both L, Lotter-Stark HC, Tsekoa T, Phahladira B, Shumba W, Chakauya E, Sabeta CT, et al. Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody. J Infect Dis. 2014;210:200–8. doi:10.1093/infdis/jiu085. PMID:24511101
   PubMed Web of Science ®Google Scholar
• CSIR. Genetically modified tobacco plants deliver a cheaper, better rabies antidote. Pretoria: Council for Scientific and Industrial Res. 2016 [ accessed June 15 2017]. http://www.techtransfer.csir.co.za/2013/01/genetically-modified-tobacco-plants-deliver-a-cheaper-better-rabies-antidote/
   Google Scholar
• Kahn RE, Clouser DF, Richt JA. Emerging infections: a tribute to the one medicine, one health concept. Zoonoses Public Health. 2009;56:407–28. doi:10.1111/j.1863-2378.2009.01255.x. PMID:19486315
   PubMed Web of Science ®Google Scholar
• Souza MJ. One health: zoonoses in the exotic animal practice. Vet Clin North Am Exot Anim Pract. 2011;14:421–426. doi:10.1016/j.cvex.2011.05.007. PMID:21872779
   PubMedGoogle Scholar
• Meseko CA, Egbetade AO, Fagbo S. Ebola virus disease control in West Africa: an ecological, one health approach. Pan Afr Med J. 2015;21:6. doi:10.11604/pamj.2015.21.6.6587. PMID:26401200
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505–518. doi:10.1016/S0140-6736(16)32621-6. PMID:28017403
   PubMed Web of Science ®Google Scholar
• Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 2001;286:384–390. doi:10.1006/viro.2001.1012. PMID:11485406
   PubMed Web of Science ®Google Scholar
• Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J. 2011;9:807–16. doi:10.1111/j.1467-7652.2011.00593.x. PMID:21281425
   PubMed Web of Science ®Google Scholar
• Monreal-Escalante E, Ramos-Vega AA, Salazar-González JA, Bañuelos-Hernández B, Angulo C, Rosales-Mendoza S. Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants. Planta. 2017;246(1):123–32, http://link.springer.com/article/10.1007%2Fs00425-017-2689-51-10. doi:10.1007/s00425-017-2689-5
   PubMed Web of Science ®Google Scholar
• Madara JJ, Han Z, Ruthel G, Freedman BD, Harty RN. The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. Future Virol. 2015;10:537–46. doi:10.2217/fvl.15.6. PMID:26120351
   PubMed Web of Science ®Google Scholar
• LeafBio http://mappbio.com/leafbio-announces-conclusion-of-zmapp-clinical-trial/ 2016
   Google Scholar
• Budzianowski J. Tobacco against Ebola virus disease. Przegl Lek. 2015;72:567–71. PMID:26946569
   PubMedGoogle Scholar
• Bukbuk DN, Dowall SD, Lewandowski K, Bosworth A, Baba SS, Varghese A, Watson RJ, Bell A, Atkinson B, Hewson R. Serological and Virological Evidence of Crimean-Congo Haemorrhagic Fever Virus Circulation in the Human Population of Borno State, Northeastern Nigeria. PLoS Negl Trop Dis. 2016;10:e0005126. doi:10.1371/journal.pntd.0005126. PMID:27926935
   PubMed Web of Science ®Google Scholar
• Ghiasi SM, Salmanian AH, Chinikar S, Zakeri S. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin Vaccine Immunol. 2011;18:2031–7. doi:10.1128/CVI.05352-11. PMID:22012978
   PubMed Web of Science ®Google Scholar
• Boshra H, Lorenzo G, Busquets N, Brun A. Rift valley fever: recent insights into pathogenesis and prevention. J Virol. 2011;85:6098–105. doi:10.1128/JVI.02641-10. PMID:21450816
   PubMed Web of Science ®Google Scholar
• Kortekaas J. One Health approach to Rift Valley fever vaccine development. Antiviral Res. 2014;106:24–32. doi:10.1016/j.antiviral.2014.03.008. PMID:24681125
   PubMed Web of Science ®Google Scholar
• Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B, et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol. 2011;85:12901–9. doi:10.1128/JVI.06046-11. PMID:21976656
   PubMed Web of Science ®Google Scholar
• Kalbina I, Lagerqvist N, Moiane B, Ahlm C, Andersson S, Strid A, Falk KI. Arabidopsis thaliana plants expressing Rift Valley fever virus antigens: mice exhibit systemic immune responses as the result of oral administration of the transgenic plants. Protein Expr Purif. 2016;127:61–7. doi:10.1016/j.pep.2016.07.003. PMID:27402440
   PubMed Web of Science ®Google Scholar
• Baudin M, Jumaa AM, Jomma HJ, Karsany MS, Bucht G, Naslund J, Ahlm C, Evander M, Mohamed N. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob Health. 2016;4:e864–71. doi:10.1016/S2214-109X(16)30176-0. PMID:27692776
   PubMed Web of Science ®Google Scholar
• Zumla A, Dar O, Kock R, Muturi M, Ntoumi F, Kaleebu P, Eusebio M, Mfinanga S, Bates M, Mwaba P, et al. Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. Int J Infect Dis. 2016;47:5–9. doi:10.1016/j.ijid.2016.06.012. PMID:27321961
   PubMed Web of Science ®Google Scholar
• He J, Peng L, Lai H, Hurtado J, Stahnke J, Chen Q. A plant-produced antigen elicits potent immune responses against West Nile virus in mice. Biomed Res Int. 2014;2014:952865. doi:10.1155/2014/952865. PMID:24804264
   PubMed Web of Science ®Google Scholar
• Lai H, Engle M, Fuchs A, Keller T, Johnson S, Gorlatov S, Diamond MS, Chen Q. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A. 2010;107:2419–24. doi:10.1073/pnas.0914503107. PMID:20133644
   PubMed Web of Science ®Google Scholar
• He J, Lai H, Brock C, Chen Q. A novel system for rapid and cost-effective production of detection and diagnostic reagents of West Nile virus in plants. J Biomed Biotechnol. 2012;2012:106783. doi:10.1155/2012/106783. PMID:22187532
   PubMedGoogle Scholar
• Aguiar M, Stollenwerk N, Halstead SB. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. PLoS Negl Trop Dis. 2016;10:e0005179. doi:10.1371/journal.pntd.0005179. PMID:28002420
   PubMed Web of Science ®Google Scholar
• Valdes I, Marcos E, Suzarte E, Perez Y, Brown E, Lazo L, Cobas K, Yaugel M, Rodriguez Y, Gil L, et al. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses. Arch Virol. 2017;162(8):2247–56; http://www.ncbi.nlm.nih.gov/pubmed/28393307 doi:10.1007/s00705-017-3360-y. PMID:28393307
   PubMed Web of Science ®Google Scholar
• Kim TG, Kim MY, Yang MS. Cholera toxin B subunit-domain III of dengue virus envelope glycoprotein E fusion protein production in transgenic plants. Protein Expr Purif. 2010;74:236–41. doi:10.1016/j.pep.2010.07.013. PMID:20691270
   PubMed Web of Science ®Google Scholar
• Kim TG, Kim MY, Huy NX, Kim SH, Yang MS. M cell-targeting ligand and consensus dengue virus envelope protein domain III fusion protein production in transgenic rice calli. Mol Biotechnol. 2013;54:880–7. doi:10.1007/s12033-012-9637-1. PMID:23250723
   PubMed Web of Science ®Google Scholar
• Kim MY, Reljic R, Kilbourne J, Ceballos-Olvera I, Yang MS, Reyes-del Valle J, Mason HS. Novel vaccination approach for dengue infection based on recombinant immune complex universal platform. Vaccine. 2015;33:1830–8. doi:10.1016/j.vaccine.2015.02.036. PMID:25728317
   PubMed Web of Science ®Google Scholar
• Gottschamel J, Lossl A, Ruf S, Wang Y, Skaugen M, Bock R, Clarke JL. Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems. Plant Mol Biol. 2016;91:497–512. doi:10.1007/s11103-016-0484-5. PMID:27116001
   PubMed Web of Science ®Google Scholar
• Dent M, Hurtado J, Paul AM, Sun H, Lai H, Yang M, Esqueda A, Bai F, Steinkellner H, Chen Q. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J Gen Virol. 2016;97:3280–90. doi:10.1099/jgv.0.000635. PMID:27902333
   PubMed Web of Science ®Google Scholar
• CDC. Yellow Fever Vaccine. Centers for Disease Control adn Prevention; 2015 [ accessed https://www.cdc.gov/yellowfever/vaccine/
   Google Scholar
• iBio. iBio Expands Commercial Collaboration With Bio-Manguinhos and Fraunhofer. 2014 [ accessed http://www.marketwired.com/press-release/ibio-expands-commercial-collaboration-with-bio-manguinhos-and-fraunhofer-nyse-mkt-ibio-1921259.html
   Google Scholar